{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-247168","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2022-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.702114+00:00","generated_at":"2026-06-23T08:51:11.517891+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Spero Therapeutics stockholders approve 2M share increase to 2017 Stock Incentive Plan","bullets":["Stockholders approved amendment to 2017 Stock Incentive Plan, increasing authorized shares by 2,000,000 (total 4,608,374 for new awards).","Vote: 11,537,809 for, 8,787,318 against, 3,114,531 abstentions, 4,552,916 broker non-votes.","Directors Patrick Vink and Frank Thomas re-elected at annual meeting on September 15, 2022.","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-247168","json":"https://secwatch.observer/filing/0001193125-22-247168.json","markdown":"https://secwatch.observer/filing/0001193125-22-247168.md","text":"https://secwatch.observer/filing/0001193125-22-247168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522247168/0001193125-22-247168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522247168/d371077d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:51:11.517891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}